Skip to main content

Table 1 Baseline characteristics, cART regimens and responses of the women who commenced cART during pregnancy

From: An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy

Values are median (IQR) or total (%)

Women initiating cART during index pregnancy and with a quantifiable HIV RNA at day 14

(n = 192)

Women initiating cART during index pregnancy and with HIV RNA below the limits of quantification at day 14

(n = 29)

Age (years)

31.0 (26.5, 34.0)

31.0 (25.5, 36.0)

Black African and/or Caribbean ethnicity

160 (83.3)

26 (89.7)

HIV acquired via heterosexual intercourse

189 (98.5)

28 (96.6)

Hepatitis B and/or C co-infection

2 (1.0)

4 (13.7)

Received cART previously

70 (36.5)

9 (31.0)

Gestational age when cART initiated, weeks

20.8 (16.9, 24.4)

21.9 (19.0, 24.3)

Baseline CD4+ T-cell count, cells/µL

339 (212, 481)

520 (334–637)

Baseline plasma HIV RNA, log10 copies/mL

4.2 (3.8, 4.7)

3.1 (2.9–3.6)

Plasma HIV RNA 14 days after initiating cART, log10 copies/mL

2.4 (2.1, 2.9)

All < 1.7

First-phase HIV RNA half-life decay, days

2.5 (2.1, 3.0)

2.9 (2.2, 3.6)

Women with pVL < 50 copies/mL at 36 weeks’ gestation

139 (72.4)

29 (100)

Women with pVL < 50 copies/mL at delivery

163 (84.9)

29 (100)

Gestational age at delivery, weeks

39.1 (38.0, 40.4)

39.0 (38.0, 40.0)

cART regimen used

  

 ABC/3TC/AZT

11 (5.7)

3 (10.3)

 Dual NRTI backbone

181 (94.3)

26 (89.7)

  AZT + 3TC

75 (39.1)

11 (37.9)

  ABC + 3TC

41 (21.4)

6 (20.7)

  TDF + FTC

65 (33.9)

9 (31.0)

 Dual NRTI backbone + PI

132 (68.8)

20 (69.0)

  Atazanavir/ritonavir

60 (31.1)

9 (31.0)

  Darunavir/ritonavir

11 (5.7)

1 (3.4)

  Lopinavir/ritonavir

50 (26.0)

3 (10.3)

  Saquinavir/ritonavir

11 (5.7)

7 (24.1)

 Dual NRTI backbone + NNRTI

32 (16.7)

2 (6.9)

  Nevirapine

26 (13.5)

2 (6.9)

  Efavirenz

5 (2.6)

0

  Rilpivirine

1 (0.5)

0

 Dual NRTI backbone + INSTI

17 (8.9)

4 (13.8)

  Raltegravir

11 (5.7)

1 (3.4)

  Dolutegravir

6 (3.1)

3 (10.3)

Infant HIV status at birth

  

 HIV negative

150 (78.1)

21 (72.4)

 Data not available

42 (21.9)

8 (27.6)

  1. Baseline characteristics, antiretroviral treatment regimens and responses of the 221 women living with HIV, who commenced combination antiretroviral therapy during index pregnancy
  2. IQR interquartile range, cART combination antiretroviral treatment, ABC abacavir, 3TC lamivudine, AZT zidovudine, TDF tenofovir disoproxil fumarate, FTC emtricitabine, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor
Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us